Fairfield, Bush & Co. Biomarin Pharmaceutical Inc Transaction History

Fairfield, Bush & Co.

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 15, 2023	BUY	$86.68 - $100.3 $338,052 - $391,170	3,900 New	3,900 $338 Million
Q3 2020 Nov 18, 2020	SELL	$71.87 - $131.03 $143,740 - $262,060	-2,000 Closed	0 $0
Q2 2020 Aug 13, 2020	BUY	$79.55 - $124.22 $159,100 - $248,440	2,000 New	2,000 $247,000

637

177M

2.01M

1.28M

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $12.4B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of Fairfield, Bush & Co., based on Form 13F filings with the SEC.

Stay updated on Fairfield, Bush & Co. with notifications on news.